A Blood Biomarker‐guided Precision Medicine Approach for Individualized Neurodegenerative Disease Risk Reduction and Treatment: The Future of Preventive Neurology?

The study concluded that higher compliance to interventions led to more significant changes in protein markers. Multi-modal interventions were most effective. Novel alpha-synuclein markers also changed, potentially aiding in evaluating interventions for Lewy Body Dementia and Parkinson's disease. These markers may serve as future outcome measures for preventive neurology care.